Bacillus Calmette-Guérin (BCG) replaced early intravesical chemotherapeutic agents as the standard of care for non-muscle-invasive bladder cancer (NMIBC) with its US Food and Drug Administration approval in 1990.
Multiple studies have proven the superiority of BCG to surgery alone, and to older single-agent intravesical chemotherapy regimens. However, new multiagent intravesical chemotherapy regimens have been developed and tested in recent years. Such regimens offer the possibility of better efficacy and/or tolerability compared to BCG. However, high-quality data comparing such regimens to BCG remain scant. We briefly review the literature regarding combination intravesical chemotherapy for NMIBC.
European urology focus. 2018 Jul 13 [Epub ahead of print]
Ryan L Steinberg, Lewis J Thomas, Michael A O'Donnell
Department of Urology, University of Iowa, Iowa City, IA, USA., Department of Urology, University of Iowa, Iowa City, IA, USA. Electronic address: .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/30017900
Go Beyond the Abstract and Read a Commentary by Lewis J Thomas, MD